All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
STAR-0310 is a novel OX40 antagonistic monoclonal antibody which has a potential best-in-class profile with a high affinity, potential for favorable safety and tolerability profile with low T cell depletion from ADCC or possible on-target cellular toxicity. STAR-0310 is a novel, affinity-matured YTE-modified (M252Y/S254T/T256E) monoclonal antibody that inhibits the OX40 receptor. STAR-0310 targets the OX40 pathway, impacting Th1, Th2 and Th17/22 pathways and preserving the regulatory T cells. STAR-0310 showed less activated T cell depletion compared to rocatinlimab, which demonstrated a 5-fold greater killing capacity; STAR-0310 showed ~75% less maximal killing on activated T cells relative to rocatinlimab.
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related TNF Receptor Products |
---|
Ozekibart
Ozekibart is an anti-TNFRSF10B monoclonal antibody. |
TAPI-0
TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM. |
Semapimod tetrahydrochloride
Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. |
BMS-566394
BMS-566394 is a potent, exceptionally selective inhibitor of TNF-α converting enzyme (TACE). |
APVO603
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.